GRAI-MATTER-LABS
4.10.2021 13:04:09 CEST | Business Wire | Press release
GrAI Matter Labs (GML), a pioneer of brain-inspired ultra-low latency computing solutions, and FRAMOS, a leading global imaging provider, will unite at VISION 2021 to create Life-Ready AI for Industrial Vision Platforms. This project is based on FRAMOS’s D435e Industrial Depth Camera and GML's GrAI VIP (Vision Inference Processor) and was formed to advance vision application development in robotics, automation, IoT-connected manufacturing, and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005462/en/
The Life-Ready AI for Industrial Vision Platforms will be built on GML's pioneering development of brain-inspired computing techniques for enhanced efficiencies that leverages FRAMOS’s state of the art stereo depth sensing technology for industrial environments through their D435e stereo depth camera. The platform offers full bodied IP66 rated cameras, or board level modules for easy and flexible integration into industrial designs, both with M12 ethernet and M8 power connectors, and are enabled with ultra low latency AI processing for applications such as orientation and tracking for robots; navigation of autonomous transport systems (AGVs); among some of the many possibilities.
GML and FRAMOS will showcase the integration of the Life-Ready AI platform and D435e Industrial Depth Camera at the Vision 2021 in Stuttgart, Germany, taking place over three days starting October 5th .
“We are proud to be working with FRAMOS to couple GML's "Life-Ready AI" chips, state-of-the-art brain-inspired computing architecture, and FRAMOS' robust D400e depth camera series, to enable many types of new low latency applications in industrial manufacturing that will allow us to bring AI processing closer to where data is generated. This collaboration enables us to realize the full potential of end-point AI, allowing for actionable insights into manufacturing operations to improve productivity and lower costs,” said Christian Verbrugge, GML Europe - Senior Director Business Development.
Ferdinand Reitze, FRAMOS Product Manager 3D, is delighted about the integration, saying: “GML successfully reduced the footprint of AI inference at the edge, while achieving best results, speed and low latency. Together with our D400e series, the Life-Ready AI chips will enable new ways to resolve todays and tomorrows challenges in robotics and automation for our customers.”
About GrAI Matter Labs
At GrAI Matter Labs we are in the business of Life-Ready AI. Artificial Intelligence as close to natural as it gets. AI that feels alive. We deliver brain-inspired chips that behave like humans. AI that makes machines act and react in real-time. AI that optimizes energy and maximizes efficiency, saving time, money, and vital natural resources. GML is led by a team of visionary and seasoned engineers and is backed by leading investors, including iBionext, 360 Capital Partners, 3T Finance, and Celeste Management.
For more information, please visit www.graimatterlabs.ai .
About FRAMOS
FRAMOS® is an imaging expert, trusted advisor, and vision solutions provider. Since 1981 FRAMOS implements the best current and emerging imaging technologies for specific customer requirements and applications. FRAMOS meets these requirements with advanced and proven imaging components from a global network of renowned partners, and proprietary IP.
More than 170 FRAMOS employees world-wide are passionate about the unlimited potential of imaging and help customers achieve the optimum results from every possible scenario. FRAMOS drives and ensures the entire product development journey. This journey starts with the careful selection of imaging components, like image sensors, lenses, through various 3D technologies, to custom development tailored to individual needs and time frames. FRAMOS listens and understands customer challenges. With innovative solutions FRAMOS ensures successful project outcomes and develops long-term customer relations.
For more information, please visit www.framos.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005462/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
